Fosun Pharma Considers Transferring RMB 3.2 Billion Compound Patents To Swiss Sellas
This article was originally published in PharmAsia News
Shanghai Fosun Pharmaceutical (Group) Co. Ltd.’s owned Chongqing Fochon Pharmaceutical Co. Ltd. discussing with Switzerland-based Sellas Clinicals Holding AG plans to transfer the patents of two compounds to Sellas at an estimated €388 million ($535.91 million) by installment.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.